ACVR2B and cancer: In addition to the muscle effects of Mstn (described and demonstrated above), activin A, also an ActRIIB ligand, induces muscle atrophy (Chen et al, 2014) and has been implicated (along with Mstn) in cancer‐induced muscle wasting (Zhou et al, 2010).